Pileseptin is now available for sale at APOTEA
Pileseptin is now available for sale at APOTEA
Double Bond Pharmaceuticals subsidiary Drugsson AB, distributor of Pileseptin in the Nordic market, reports that Pileseptin in both gel and spray form is now available at Apotea. Earlier this year become the product available on Apotek365 and Meds.se.
"We are happy to have our first non-prescription product on the market in both its forms in the largest online pharmacy and work to establish a deal with several other sales channels in the future," comments Igor Lokot, CEO at Double Bond Pharmaceutical and Drugsson AB, - We continue also to look for new, sought-after products that may be of interest to Drugssons pipe line ”
More about Pileseptin: It's a new treatment for hemorrhoids that works effectively by reducing swelling and keeping the area clean from bacteria and dirt. Pileseptin Spray is used against external hemorrhoids and Pileseptin Gel against internal hemorrhoids. Pileseptin is the only product of its kind to abaite hemorrhoids and not just the symptoms.
More about Drugsson AB: www.drugsson.com
____________________________________________________________________
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Blog: http://blog.doublebp.com
Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!
_______________________________________________________________________________
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.